<p>根据 4 月 25 日的文件，Amplitude Surgical 75.4% 的股东与 Zydus Lifesciences 签署了出售大部分股份的协议，价格为每股 6.25 欧元。</p>
<p>考虑到之前的两项股份购买协议，这家印度制药公司已承诺收购法国骨科技术公司 85.6% 的股份。该区块交易预计将在第三季度完成，前提是满足交割条件。</p>
<p>由于其他少数股东也承诺将其股份进行要约，Zydus 预计将收购超过 90% 的公司股份，并实施剩余股份的强制收购程序。</p>

<p>Amplitude Surgical 75.4% 的股东已同意以每股 6.25 欧元的价格将其多数股权出售给 Zydus Lifesciences。包括之前的协议，Zydus 将收购这家法国骨科公司的 85.6% 股权。该交易预计将在第三季度完成，具体取决于相关条件。随着其他少数股东也同意出售，Zydus 预计将收购超过 90% 的股份，并启动对剩余股份的强制收购</p>

<p>Holders of 75.4% of Amplitude Surgical's  shares entered an agreement with Zydus Lifesciences for the sale of the majority stake for 6.25 euros apiece, according to an April 25 filing.</p>
<div class="lb-trans"><p>根据 4 月 25 日的文件，Amplitude Surgical 75.4% 的股东与 Zydus Lifesciences 签署了出售大部分股份的协议，价格为每股 6.25 欧元。</p>
</div><p>Counting two prior share purchase agreements, the Indian pharmaceutical company has committed to buying 85.6% of the French orthopedic technology company. The block deal is expected to close in the third quarter, subject to the satisfaction of closing conditions.</p>
<div class="lb-trans"><p>考虑到之前的两项股份购买协议，这家印度制药公司已承诺收购法国骨科技术公司 85.6% 的股份。该区块交易预计将在第三季度完成，前提是满足交割条件。</p>
</div><p>As other minority shareholders of Amplitude have also committed to tender their shares, Zydus expects to acquire over 90% of the company and implement a squeeze-out procedure for the remaining shares.</p>
<div class="lb-trans"><p>由于其他少数股东也承诺将其股份进行要约，Zydus 预计将收购超过 90% 的公司股份，并实施剩余股份的强制收购程序。</p>
</div>

Amplitude Surgical 的股东达成协议，将 75.4% 的股权出售给 Zydus Lifesciences